KS, DOX-SL: FDA Hearing February 14

The Oncologic Drugs Advisory Committee will consider approval of DOX-SL, for persons with AIDS-related Kaposi's sarcoma who have failed systemic chemotherapy, either because of toxicity or because of disease progression. This meeting, which is open to the public, will be at the FDA's Parklawn Building, in Rockville, Maryland. Persons interested in speaking should call Adele Sefried at the FDA, 301/443-4695, by February 10.

It is particularly important for physicians or patients with personal experience with DOX-SL to address the committee. Later in that meeting, the committee will also consider approval of Zoladex (goserelin acetate) for palliative treatment of advanced breast cancer in pre- and peri- menopausal women.